>
Trump Seems on the Verge of His Last Fatal Mistake. "Netanyahu Insistence." "Trump Re
Coming Collapse of Saudi Arabia--and What It Means for the Dollar
Europe's Humiliating Decline as China and Russia Reshape the World Order
The Imperial Propagandists Are Exposing Themselves Like Never Before
Dubai Just Finished the World's First Permanent Air Taxi Route: Airport to the Marina in Under 1
Doroni Aerospace Raises More than $60m for H1?X Development
After 13 Years Battling Cancer, a 61-Year-Old Brazilian Man Achieved Complete Remission...
Extraterrestrial habitats may rise via Legos of laser-fused moon dust
Battery-only 19-seater puts China in the electric airliner race
Dream Chaser space plane gets landing approval for debut mission in 2027
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever

Patients with an inherited disease that caused them to lose much of their sight early in childhood experienced a quick return of vision after they received gene therapy.
The new treatment addressed the genetic mutation that caused their vision's deterioration, letting them see 100 times better than before.
Some patients even experienced a 10,000-fold improvement in their vision after receiving the highest dose of the therapy, according to researchers from the University of Pennsylvania's School of Medicine.
"One patient reported for the first time being able to navigate at midnight outdoors only with the light of a bonfire."
A total of 15 people participated in the Phase 1/2 trial, including three pediatric patients. Each patient suffered from Leber congenital amaurosis (LCA1) as a result of mutations in the GUCY2D gene, which is essential to producing proteins critical for vision. The rare condition, which affects 100,000 people worldwide, causes significant amount of vision loss as early as infancy.
All subjects had severe vision loss with their best measure of vision being equal or worse than 20/80—meaning if a typically-sighted person could see an object clearly at 80 feet, these patients would have to move up to at least 20 feet to see it. Glasses provide limited benefit to these patients because they correct abnormalities in the optical focusing ability of the eye, and are unable to address medical causes of vision loss, such as genetic retinal diseases like LCA1.